argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021
21 Octobre 2021 - 07:00AM
October
21,
2021Breda, the
Netherlands – argenx (Euronext & Nasdaq: ARGX), a
global immunology company committed to improving the lives of
people suffering from severe autoimmune diseases and cancer, today
announced that it will host a conference call and audio webcast on
Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss
its third quarter 2021 financial results and provide a business
update.
A webcast of the live call may be accessed on
the Investors section of the argenx website at
argenx.com/investors. A replay of the webcast will be available on
the argenx website for approximately one year following the
call.
Dial-in numbers:
Please dial in 15 minutes prior to the live
call.
Belgium
0800
389
13France 0805
102 319Netherlands
0800
949 4506United Kingdom
0800 279 9489United
States
1
844 808 7140International
1
412 902 0128
About argenx
argenx is a global immunology company committed to improving the
lives of people suffering from severe autoimmune diseases and
cancer. Partnering with leading academic researchers through its
Immunology Innovation Program (IIP), argenx aims to translate
immunology breakthroughs into a world-class portfolio of novel
antibody-based medicines. argenx is evaluating efgartigimod in
multiple serious autoimmune diseases. argenx is also advancing
several earlier stage experimental medicines within its therapeutic
franchises. argenx has offices in Belgium, the United States,
Japan, and Switzerland. For more information, visit
https://www.argenx.com and follow us on LinkedIn and Twitter.
For further information, please contact:
Media:
Kelsey Kirkkkirk@argenx.com
Joke Comijn (EU)jcomijn@argenx.com
Investors:
Beth DelGiaccobdelgiacco@argenx.com
Michelle Greenblattmgreenblatt@argenx.com
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Argen X (EU:ARGX)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024